BRCA2 and cancer: This mechanism of resistance is clinically relevant for BRCA-mutated cancer patients treated with platinum therapy: up to 46% of platinum-resistant BRCA mutated HGSOC exhibits tumor-specific secondary mutations that restore the ORF of either BRCA1 or BRCA2.